



**DELIVERY VIA ELECTRONIC MAIL: [pharmacy.board@bop.oregon.gov](mailto:pharmacy.board@bop.oregon.gov)**

**REQUEST FOR ACKNOWLEDGEMENT OF RECEIPT**

November 10, 2022

Joseph Schnabel, Executive Director  
Oregon Board of Pharmacy  
800 NE Oregon Street, Suite 150  
Portland, Oregon 97232

State Letter

Dear Mr. Schnabel:

The purpose of this letter is to notify you, the Oregon Board of Pharmacy (BoP), that the U.S. Food and Drug Administration does not intend to take further action with regard to an inspection of a pharmacy you licensed, Pet Pharmacy NW LLC, formerly known as Health Solutions Pharmacy Center, Inc. dba Professional Compounding Pharmacy, located at 996 NW Circle Boulevard, Suite 105, Corvallis, Oregon 97330-1485.

FDA inspected the firm on June 21, 2022, as a follow-up to our inspection of Health Solutions Pharmacy Center, Inc. dba Professional Compounding Pharmacy from December 10, 2018, to January 28, 2019, and the Warning Letter issued to the firm on March 31, 2020. You were informed of the inspection but did not accompany the FDA investigator during the inspection.

During the June 21, 2022, inspection, the FDA investigator reviewed the practices at the facility and found the firm is under new ownership and is no longer compounding sterile or non-sterile human drug products. No Form FDA 483 was issued to the firm. The investigator could not verify corrective actions, as the firm had ceased operations with respect to the issues presented in the Warning Letter. Therefore, FDA does not intend to take further actions at this time related to conditions of section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act). However, the Warning Letter will remain open indefinitely.

FDA believes that this firm can be appropriately overseen by the state. Please notify us if you become aware the previous owner has resumed any compounding operations, opens another compounding pharmacy, if there are any adverse events or product quality concerns associated with drug products made at this facility, or if you observe any practices at this facility that concern you or that could be violations of federal law.

We look forward to continuing to work with you on the oversight of compounding pharmacies. If you have additional questions, please contact William V. Millar, compliance officer by email at [william.millar@fda.hhs.gov](mailto:william.millar@fda.hhs.gov) and reference unique identifier CMS WA 459602 in your correspondence.

Division of Pharmaceutical Quality Operations IV  
19701 Fairchild Road, Irvine, CA 92612-2506  
Telephone: 949-608-2900  
Fax: 949-608-4417  
[www.fda.gov](http://www.fda.gov)

Sincerely,

A handwritten signature in black ink, appearing to read "Steven Porter".

CDR Steven E. Porter, Jr.  
Director, Division of Pharmaceutical Quality Operations IV

SP:wm

FEI 3014597434

Cc:  
Gene Vang, Owner and Pharmacist-In-Charge  
Pet Pharmacy NW LLC  
996 NW Circle Boulevard, Suite 105  
Corvallis, Oregon 97330-1485  
[petpharmacynw@gmail.com](mailto:petpharmacynw@gmail.com)